We use cookies on our website, which are text files containing small amounts of information that are downloaded to your computer or mobile device. To find out more about the cookies we use please click here.

Some of these cookies are strictly necessary for operation of this site. Other, non-essential cookies are used for measuring website performance (which is all aggregated and anonymised) and may share this information with Google. To consent to non-essential cookies, click "Accept all non-essential cookies".

Peter Dines

Chief Operating Officer & Head of Life Sciences & Biosciences

About

Peter joined the Group in 2015 as Head of Life Sciences & Biosciences, with over 20 years' experience in this sector, and in addition became Chief Operating Officer in 2018. He is responsible for a number of the life science portfolio investments including Native Antigen, Aston Eyetech, Sarissa Diagnostics, Nuvision, and Intelligent Health. Peter is also the Fund Manager for Mercia Growth Funds with overall responsibility for SEIS/EIS Funds across the four Mercia sectors and leads the Senior Management Team.

Previous experience

Peter has been involved with a number of turnarounds and exits within the sector, including the acquisition of Surgicraft’s loss-making business where, as managing director, sales quadrupled within three years and the business was subsequently sold to a private equity backed business and Diagnostic World, a fast-growing diagnostic provider to the NHS.

© Mercia Technologies 2018

Terms and conditions Privacy policy

Designed and built by Onespacemedia